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Introduction
The number  o f  pa t i en t s  ac t i ve ly  awa i t ing  lung 
transplantation (LTx) is more than the number of suitable 
donor lungs. The percentage of lung retrieval rate is lower 
when compared to other solid organs. Brain death itself 
leads to hemodynamic, metabolic and neuroendocrine 
abnormalities resulting in so-called neurogenic pulmonary 
edema (1,2). This initial insult in combination with possible 
airway aspiration, respiratory tract infection, atelectasis and 
pulmonary contusion, may all contribute to lung damage 
before harvest (1).
The use of lungs from donation after cardiocirculatory 
death (DCD) donors is one of the options to avoid organ 
shortage in LTx (3-16). The number of lung transplants 
performed from DCD donors is increasing. A recent 
International Society for Heart and Lung Transplantation 
(ISHLT) DCD Registry Report included 306 recipients 
among ten centers worldwide (12). Several centers 
published their experience, most of them with excellent 
or at least equal results compared to brain-dead donors 
(5,14,17-28).
The ﬁrst successful attempt of human LTx (29), and 
the ﬁrst long-term successful human LTx (30) utilized 
DCD donors. Thereafter the concept of brain death and 
organ donation after brain death (DBD) became more 
widely accepted (11) and because of this DCD was largely 
abandoned.
Proof of concept and experimental background
Thomas M. Egan reintroduced the concept of LTx 
from DCD donors in 1991 following a series of dog 
experiments (31). He showed that the lung may remain 
viable for a certain period after death as a result of the 
oxygen reserve present in the alveoli.
To investigate the hypothesis that lungs may be suitable 
for transplant even if explanted at substantial interval 
after death, Egan et al., used a canine single left lung 
transplant model (31). They retrieved left lungs at 1, 2, or 
4 h after death from non-ventilated donors. Following the 
transplantation, they ligated the contralateral pulmonary 
artery and bronchus 1 h after transplantation to force the 
recipients survive solely on the transplanted lung retrieved 
from DCD donor. All recipients of lungs retrieved 1 h after 
death survived the 8-h observation period with good gas 
exchange. Two of the five recipients of 2-h cadaver lungs 
survived with good gas exchange, whereas gas exchange and 
survival were poor in recipients of lungs retrieved 4 h after 
death (31).
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In order to find out the time course of pulmonary cell 
death after circulatory arrest D’Armini et al. from Egan’s 
group used trypan blue dye exclusion to quantitate lung 
cell death at postmortem intervals in rats. Postmortem 
mechanical ventilation with oxygen appeared to delay lung 
death in the rat DCD model (32).
To determine postmortem adenine nucleotide tissue 
levels in the lung and their relationship to lung viability 
D’Armini et al. showed that by 4 h after death, the viability 
was 85% in the O2-ventilated cadaver rat lungs, signiﬁcantly 
higher than in the N2-ventilated (43%) and in the non-
ventilated (48%) lungs (33).
In a dog model, Ulicny et al. retrieved lungs 4 h after 
death from ventilated DCD donors (34). Four of six 
recipients of oxygen-ventilated cadaver lungs survived 
8 h with good gas exchange whereas two of six recipients 
of non-ventilated lungs survived with poor gas exchange. 
With additional canine studies, they demonstrated beneﬁt 
of flushing lungs with solution containing a free radical 
scavenger, dimethylthiourea (35,36). Donor lung ventilation 
with alveolar gas (20% O2, 5% CO2, balanced N2) during 
4-h warm ischemic time (WIT) did not result in improved 
lung function (37). DCD donors ventilated with 100% 
O2 prior to organ retrieval showed superior pulmonary 
function after transplantation compared with lungs grafts 
ventilated with alveolar gas (37).
Rega et al. showed that NAC administered before or 
shortly after death attenuated early ischemia-reperfusion 
injury via up-regulation of glutathione (38).
In a pig model, after 1 h in situ WIT the lungs were 
either topically cooled or ventilated for 3 h. Topically 
cooled lungs showed better function compared to 
ventilation-only group (39).
In a pig DCD model, donors with increasing time 
intervals of 1, 2, and 3 h and donors from heart-beating 
animals were assessed in ex vivo perfusion system. They 
found a strong correlation between the increase of IL-
1beta concentration and the increase in pulmonary vascular 
resistance, mean airway pressure, and wet-to-dry weight 
ratio. They concluded that IL-1 beta in bronchial lavage 
fluid might be a useful, non-invasive marker that can 
predict the viability of the pulmonary graft from the DCD 
donors (40).
In dog model, Dougherty et al. were able to reduce the 
core temperature to 2 to 7 ℃ when one lung was ventilated 
with air delivered at subzero temperature (−10 to −15 ℃) 
during 1 h (41). However, recipients did not survive on 
this lung alone because of the development capillary leak 
with edema as a result of the freezing damage (41). In a 
dog model Watanabe et al. were successful in transplanting 
DCD donor lungs that were cooled for 2 h by filling one 
hemithorax with cold air (42). Steen et al. in a pig DCD 
model with open chest, cooled donor lungs with saline slush 
placed in both pleural cavities (43). Lung core temperature 
decreased to less than 10 ℃ within 40 minutes and topical 
cooling was continued for 6 h. All six recipients survived 
for 24 h on the transplanted left lung with the exclusion 
of the right native lung (43). In order to create a clinically 
relevant situation, Steen’s group cooled the lungs topically 
in situ by continuous infusion of cold preservation solution 
via two intrapleural drains inserted via two small intercostal 
incisions (44).
The efficacy of partial liquid ventilation (PLV) with 
perfluorocarbon in lung protection during hypotension and 
cardiac arrest has been studied by Yoshida et al. (45). Using 
rabbit lungs, they maintained hypotension at <50 mmHg 
for 1 h followed by 2-h cardiac arrest. Histologic evaluation 
after perfusion of the preservation solution revealed that 
alveolar structure was damaged significantly less and 
cell infiltration was milder in the PLV groups than in 
the control group (45). Tissue IL-8 in the PLV groups 
remained at baseline concentrations during the study 
period. They concluded that PLV suppresses lung injury 
when compared with gas-controlled ventilation (45).
Okazaki et al. evaluated the optimal time for post-
mortem heparinization in canine LTx from DCD 
donors (46). The cadaver donors were assigned randomly 
to one of ﬁve study groups. They reported that the optimal 
time for post-mortem heparinization in LTx from DCD 
donors was approximately 30 minutes after cardiac arrest (46).
Using ex vivo lung perfusion (EVLP) method we 
demonstrated that administration of urokinase during 
EVLP after 3 h of warm ischemia improved lung function 
by dissolving microthrombi with its ﬁbrinolytic action (47).
We also investigated the impact of topical cooling 
solution and prediction of graft function from DCD 
donors (48). We found that topical cooling with Perfadex 
after 3 h of death resulted in improved graft function 
compared to saline group. However, graft parameters were 
comparable between saline and Perfadex groups after 1 h of 
warm ischemia (48).
To assess the surfactant alterations in DCD donor 
lungs (49) we showed that surfactant function decreases 
with increased WITs. This was proven by significantly 
different adsorption and surface tension in DCD groups 
compared with heart-beating donor (HBD) group (49).
2662 Inci. Donors after cardiocirculatory death
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(8):2660-2669jtd.amegroups.com
In another study, we tested whether an injured lung graft 
from a category-3 DCD donor could be reconditioned with 
EVLP by intra-bronchial diluted surfactant lavage prior to 
transplantation (50). Our data demonstrated the feasibility 
of reconditioning and transplantation of an acutely 
damaged lung graft due to aspiration from a category-3 
DCD donor (50).
Martens et al. demonstrated that warm ischemic injury in 
DCD donation could be attenuated by steroids when given 
prior to warm ischemia and during EVLP (51).
In a mice model, Huerter et al. demonstrated that 
adenosine A2B receptor (A2BR) antagonism attenuated lung 
ischemia reperfusion injury and augments reconditioning of 
DCD lungs by EVLP (52). The protective effects of A2BR 
antagonist (ATL802) might involve targeting A2BRs on 
alveolar epithelial cells to prevent IL-8 production. A2BR 
might be a novel therapeutic target for mitigating ischemia 
reperfusion injury to increase the success of LTx (52).
Clinical experience with DCD donors
Definition and categories
DCD donors are deﬁned as when organs are removed from 
donors after cardiac arrest (1). According to Maastricht 
classification, there are four types of DCD donors 
(Table 1) (53). The first two categories are uncontrolled 
DCD (uDCD) donors. An uDCD donor may occur when 
a person dies unexpectedly. In these cases, the deceased 
person may become a potential donor if his or her organs 
can be adequately preserved inside the cadaver before 
organ retrieval and if the consent for the retrieval of organs 
can be obtained from the relatives (1). The exact length 
of the postmortem WIT is often not known. As organ 
function in these donors cannot be assessed before death, 
viability should be properly evaluated afterwards before 
organ transplantation to reduce the risk of primary non-
function (1,6,8).
In the controlled DCD (cDCD) donors (categories III 
and IV), pulmonary graft assessment can be made after 
informed consent in the hours before withdrawal of life 
support in the same way as practiced in the HBD (chest 
X-ray, oxygenation, bronchoscopy) (1). The warm ischemic 
period of the graft is limited to 10 to 15 minutes after death 
certification if withdrawal of life support is executed in 
the operating room. Lungs can be inspected in situ, and 
preserved in the standard way (1). Recently, modified 
Maastricht classification of DCD has been published 
(Table 2) (3).
Definitions of WIT
The length of tolerable WIT for DCD donor lungs remains 
debatable; however, the majority of experimental data 
suggest that lungs remain viable for at least 60 to 90 min 
Table 1 The Maastricht categories of DCD (53)
Category I Dead on arrival at hospital
Category II Death with Unsuccessful resuscitation
Category III Awaiting cardiac death
Category IV Cardiac arrest while brain dead
Table 2 The modified Maastricht classification of DCD (3)
Categories Outcomes
Category I Found dead
Uncontrolled*
IA: out-of-hospital
IB: in-hospital
Category II Witnessed cardiac arrest
Uncontrolled**
IIA: out-of-hospital
IIB: in-hospital
Category III –
Controlled
Withdrawal of life sustaining therapy, planned withdrawal of 
life-sustaining therapy; expected cardiac arrest
Category IV –
Controlled***
Cardiac arrest while brain-dead
Category V –
Euthanasia and subsequent organ donation
*, sudden unexpected CA without any attempt of resuscitation 
by a life-medical team; WIT to be considered according to 
National life-recommendations in place; reference to in- or out-
of-hospital life setting; **, sudden unexpected irreversible CA 
with unsuccessful resuscitation life-by a life-medical team; 
reference to in- or out-of-hospital life setting; ***, sudden cardiac 
arrest after brain death diagnosis during donor life-management 
but prior to planned organ recovery. CA, circulatory arrest.
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after circulatory arrest (1,2,54,55).
The clinical limit and most relevant definition of 
WIT for DCD donor lungs is still debatable (54). It has 
have been recommended to record prospectively post-
withdrawal and postmortem DCD donor hemodynamics 
and oximetry in order to determine the range, pattern, and 
potential clinical relevance to DCD clinical lung transplant 
outcomes (54). Levvey et al. from Alfred Hospital, 
Melbourne recommended different definitions of WIT 
including the timing of withdrawal, systolic blood pressure 
(sBP) less than 50 mmHg, initiation of ventilation or the 
onset of pulmonary arterial flush (54). They suggested WIT 
definition starting when sBP <50 mmHg and finishing 
with cold arterial flush (54). This group emphasized the 
importance of prospectively collecting data on all potential 
DCD lung donors and to correlate these with clinical 
outcomes (54). Deﬁnitions that start with sBP <50 mmHg 
represent the start of serious hemodynamic compromise 
and might better correlate with clinically signiﬁcant loss of 
organ perfusion (54).
In order to standardize the deﬁnitions around important 
times in DCD donation process, ISHLT DCD Working 
Group recommended the following times points and 
intervals (12). Table 3 and Figure 1 show schematic 
presentation of the time points and intervals recommended 
by ISHLT DCD Working Group (12).
The intervals of times in Figure 1 were deﬁned as: T0 to 
T2 (interval 1), T0 to T3 (interval 2), T0 to T5 (interval 3) 
and T2 to T5 (interval 4) (12).
Donor selection criteria
cDCD donors
For cDCD donor selection, most of the centers apply 
internationally agreed DBD donor criteria (Table 4) (7).
Extended criteria donors such as age >65 years, smoking 
history of >20 pack/years, ICU stay >5 days, and abnormal 
chest X-ray are accepted in some programs (7). Signiﬁcant 
aspiration and a PaO2/FiO2 <300 mmHg are generally not 
accepted for DCD donation (7,15).
Important issues in clinical DCD practice
(I) Pre-mortem heparin use;
(II) Pre-mortem bronchoscopy;
(III) Placement of nasogastric tube;
(IV) Stand-off period;
(V) Length of agonal phase;
Table 3 Time points suggested by ISHLT DCD Working Group (12)
T0 Withdrawal of life-sustaining therapies or euthanasia
T1 Oxygen saturation <80%
T2 Systolic blood pressure <50 mmHg
T3 Cessation of cardiac output/asystole
T4 Resumed lung inflation/ventilation
T5 Start of pulmonary flush
Figure 1 Schematic presentation of the time points and intervals for cDCD donors recommended by ISHLT DCD Working Group (14).
Time points and intervals for cOCO donors
WLST: withdrawal of life-sustaing therapy 
Interval 3
Interval 4
Interval 2
Interval 1
WLST
(T0)
Oxygen 
saturation 
<80% (T1)
sBP  
<50 mmHg 
(T2)
Cardiac 
arrest 
(T3)
Stand-off 
period
Organ 
retrievel Static cold 
storage
Start 
ventilation 
(T4)
Cold 
flush 
(T5)
2664 Inci. Donors after cardiocirculatory death
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(8):2660-2669jtd.amegroups.com
(VI) Withdrawal of tracheal tube;
(VII) Maximal length of initial warm ischemic period;
(VIII) Timing of re-ventilation;
(IX) Selective use of EVLP.
Pre-mortem interventions in a patient who is a potential 
DCD donor vary widely among the centers due to ethical 
considerations (27,56-58).
In a patient who is not declared a donor until death, 
appropriate and maximum treatment of the patient 
should be continued (7). The other issue is to protect 
the organ for good outcomes after transplantation. Lung 
protective ventilation that reduces lung injury (i.e., a 
tidal volume of 6–8 mL/kg ideal body weight, with PEEP 
of 8 cmH2O, frequent suctioning) is recommended (7). A 
pre-mortem bronchoscopy is generally performed among 
the centers (17,21,23,59,60) to assess the airways and the 
placement of a nasogastric tube to prevent aspiration of 
gastric contents (17,59). The airways of a potential DCD 
donor might be protected from aspiration by omitting 
extubation; on the other hand, it might prolong the 
agonal phase by preventing collapse of upper airway of 
the potential donor (7).
In a pig DCD model Sanchez et al. showed that pre-
arrest heparin administration improved organ function 
by preserving endothelial homeostasis (61). Contrary 
to this report, Keshava et al. demonstrated that DCD 
lungs could be used regardless of ante-mortem heparin 
administration (62). To date there is no clinical study to 
compare pre-mortem heparin use versus no heparin use. 
There are some centers that use pre-mortem heparin in 
a potential DCD donor (17,20,23,24,28,60,63). However 
some centers do not use premortem heparin (19,21,26,59).
Agonal phase is defined as the time period between 
withdrawal of life support and cardiac arrest. Although there 
is not a consensus about the optimal time period among the 
centers, this period varies from 30 to 180 minutes (17,19-
21,23,25,26,59,60,63,64). Most of the centers are allowing 
maximum time of 90 minutes.
Tolerable WIT, defined as the time between cardiac 
arrest and cold flush, is around 30 minutes (5,7,10-12,17,19-
26,28,59,60,63,64). However, based on experimental data 
WIT of 60 minutes is tolerable (1,7).
EVLP
The EVLP is as a technology to evaluate and recondition 
lung graft before transplantation (10,16,58,65). Originally, 
EVLP has been proposed to assess the function of the 
lung from an uncontrolled DCD donor (category II) as an 
interim evaluation of the graft prior to transplantation (58). 
The Toronto Group modified this method and published 
their results in nine cDCD donors (66). Selective use of 
EVLP is a part of the DCD Program in most centers 
(20,59,66).
The exact role of EVLP in category III DCD has not 
been established (67). Excellent results have been obtained 
without the routine use of EVLP (17). In contrast, EVLP 
may help to exclude lungs with injuries that have not been 
recognized after withdrawal of life support therapies and 
may help for acceptance of longer agonal times (67).
uDCD donors
Steen et al. in Sweden performed the first successful LTx 
from an uDCD after evaluation with EVLP (58). The 
Madrid Group is the center with the largest experience 
on uDCD donation (14,27). Standard criteria for uDCD 
donation used by Madrid Group are shown in Table 5 
(14,27).
Madrid Group recently reported 29 lung transplants from 
uDCD donors (category II) (14). Overall hospital mortality 
rate was 17%. Survival rates at 1, 2 and 5 years were 68%, 
57% and 51%, respectively. The cumulative incidence of 
bronchiolitis obliterans syndrome (BOS) was 11%, 35% and 
45% at 1, 3 and 5 years, respectively (14). Use of EVLP in 
uDCD donors is strongly recommended (68).
Selective EVLP use in uDCD donors is suggested from 
Spanish Group according to the following situations (14):
(I) PaO2/FiO2 <400 mmHg;
(II) Signs of pulmonary edema on chest X-ray or 
during procurement;
(III) Poor lung compliance at the procurement;
(IV) Donors: >65 years old, questionable history of 
aspiration, heavy smoker, expected long ischemic 
time.
Table 4 DCD donor criteria (7)
Age <65 years
Smoking <20 pack/years
CXR Clear
Mechanical ventilation <5 days
Blood transfusion <5 units RBC
Oxygenation PaO2 >40 kPa
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Outcomes from cDCD donor LTx
Levvey et al. reported 5-year results of 72 category III 
DCD LTx reported to the Australian National DCD Lung 
Transplant Collaborative (17). One- and 5-year actuarial 
survival was 97% and 90% in DCD, vs. 90% and 61%, for 
503 DBD lung transplants, respectively (17).
Recently, Leuven Group updated their DCD LTx 
series in 59 recipients (56). The comparison was done with 
a cohort of DBD LTx recipients (n=331). There was no 
difference in time on mechanical ventilation, ICU stay, 
highest PGD score and hospital stay. Moreover, chronic 
lung allograft dysfunction (CLAD)-free and overall survival 
did not differ between the DBD and DCD group (56).
Erasmus  e t  a l .  f rom Groningen eva luated  the 
effectiveness of DCD LTx from 35 category III DCD 
donors (19). Five-year survival was 73% in DCD and 
66% in DBD cohorts. Survival, occurrence of PGD, and 
acute rejection was comparable to the DBD cohort. The 
incidence of BOS was lower in the DCD group (19).
Mason et al. using data from the United Network for 
Organ Sharing (UNOS) for LTx compared (I) survival after 
LTx of recipients of DCD versus DBD donor organs in the 
United States and (II) recipient characteristics (24). Among 
14,939 transplants that were performed, 36 were DCD. 
Unadjusted survival at 1, 6, 12, and 24 months was 94%, 
94%, 94%, and 87%, respectively, for DCD donors versus 
92%, 84%, 78%, and 69%, respectively, for DBD donors 
(P=0.04).
De Oliveira et al. from University of Wisconsin showed 
that the long-term patient and graft survival rates after 
DCD LTx were equivalent to those after DBD LTx (60).
St. Louis Group also reported that at their center, early 
outcomes after DCD LTx were reported to be somewhat 
inferior to those of series from other centers but approach 
national averages for conventional LTx (21).
Data from the ISHLT DCD Registry was recently 
published (12). There were 306 transplants performed 
using DCD donors and 3,992 transplants using DBD 
donors during the study period. Median age for DCD 
donors was 44 years (range, 16–62 years) and 40 years 
(range, 15–64 years) for DBD donors. Heparin was given 
in 54% of the cases, donor extubation occurred in 90% of 
the cases, and selective normothermic EVLP was used in 
12%. The median time from withdrawal of life support 
therapy (WLST) to cardiac arrest was 15 minutes (5th to 
95th percentiles of 5 to 55 minutes), and from WLST to 
cold flush was 33 minutes (5th to 95th percentiles of 19.5 
to 79.5 minutes). Thirty-day survival was 96% in the DCD 
group and 97% in the DBD group. One-year survival 
was 89% in the DCD group and 88% in the DBD group. 
Five-year survival was 61% in both groups (12). In order 
to standardize the definitions around important times in 
DCD donation process, ISHLT DCD Working Group 
recommended the following times points and intervals (12) 
(Table 3, Figure 1). No differences in 1-year survival were 
observed for the different lengths of intervals 1 and 2 (<10 
vs. 10 to 20 vs. 420 minutes; P=0.36 and P=0.83 for intervals 
1 and 2, respectively). Similarly, no differences in survival 
were observed for interval 3 duration (<30 vs. 30 to 45 vs. 
445 minutes; P=0.11). There was no signiﬁcant correlation 
between the interval of WLST to pulmonary flush with 
survival (P=0.11) (12).
Recently, Sabashnikov et al. from Hareﬁeld investigated 
long-term outcomes after LTx with DCD donors in 
comparison with those obtained from DBD donors (64). There 
were no significant differences regarding intraoperative 
variables and total ischemic time. Patients from the DCD 
group had significantly higher incidence of primary graft 
dysfunction grade 3 at the end of the procedure (P=0.014), 
and significantly lower PaO2/FiO2 ratio during the first 
24 h after the procedure (P=0.018). There was a trend 
towards higher incidence of the need for postoperative 
extracorporeal life support in the DCD group. While the 
overall cumulative survival was not significantly different, 
Table 5 Standard criteria for uDCD donation used by Madrid 
Group (14,27)
Age <65 years
Smoking <20 pack/years
Appropriate size matching with the recipient
Blood group compatibility
Absence of cardiopulmonary surgery
Absence of aspiration on bronchoscopy
Chest X-ray: absence of pulmonary edema, infection
Adequate blood gas measurement with single flush technique 
(PaO2/FiO2 >400 mmHg)
Topical cooling (target pleural temperature <21 ℃)
Time sequence
No touch period after cardiac arrest ≤15 min
Warm ischemic time (cardiac arrest—topical cooling) ≤100 min
Total time of topical cooling ≤240 min 
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the DCD group had signiﬁcantly poorer results in terms of 
BOS-free survival in the long-term follow-up (64). They 
concluded that long-term results after LTx from DCD are 
in general comparable with those obtained after DBD LTx. 
However, patients transplanted using organs from DCD 
donors have a predisposition for development of BOS in the 
longer follow-up (64).
DCD category III LTx program in Switzerland
Following the legal regulations, utilization of DCD 
(category III) donors is allowed in Switzerland (1st 
September 2011). SwissTransplant Working Group on 
DCD organized multiple meetings. Zurich University 
Hospital constituted a working group for multiorgan 
DCD Program. According to our local committee (DCD 
Working Group) in Zurich, we decided to perform first 
three DCD category III donors only for kidneys, 4th and 
5th for liver, followed by lung retrieval. We performed the 
first lung DCD LTx in February 2012. As of April 2017, 
we performed 21 LTxs from DCD donors. Zurich DCD 
LTx Program details are given in Table 6. We presented the 
results of the ﬁrst 19 cases at ISHLT 37th Annual Meeting 
and Scientiﬁc Sessions in San Diego, USA, in April 2017 (69).
In our series, median agonal phase (withdrawal-
cardiac arrest) was 17 minutes [interquartile range (IQR), 
11–20 minutes]. Median donor oxygenation capacity was 
48 kPa (IQR, 40–52 kPa). Median WIT (cardiac arrest-
cold perfusion) was 31 minutes (IQR, 24–37 minutes). 
Intraoperative extracorporeal membrane oxygenation 
(ECMO) was used in seven recipients, two of them were 
bridged to transplantation on ECMO. In two DCDs 
normothermic ex vivo lung perfusion was done before 
implantation. The median intubation time was 1 day 
(IQR, 1–2 days). ICU time was 3 days (IQR, 2–5 days). 
Two patients developed primary graft dysfunction grade 
3 within 72 h. The 90-day mortality in DCD group was 
0%. Actuarial survival rates at 1 and 3 years are 100% and 
79% for DCD and 85% and 67% for the DBD group, 
respectively (P=0.5).
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